Literature DB >> 33608999

Epigenetics of ankylosing spondylitis: Recent developments.

Hui Yang1,2, Yuting Chen1,2, Wei Xu1,2, Ming Shao1,2, Jixiang Deng1,2, Shanshan Xu1,2, Xing Gao1,2, Shiyang Guan1,2, Jinian Wang1,2, Shengqian Xu3, Zongwen Shuai3, Faming Pan1,2.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease which mainly affects the spine, sacroiliac joint and peripheral joints. To date, the exact causes and pathogenesis of AS still remain unknown. It is considered that the pathogenesis of AS is associated with genetic, infection, environment, immunity and other factors. Among them, the role of genetic factors in the pathogenesis of AS has been studied most deeply. However, over the past few years, the function of environmental predisposition and epigenetic modification in the pathogenesis of AS has received extensive attention. This paper summarizes the recent progress in the epigenetics of AS, including abnormal epigenetic modifications at AS-associated genomic loci, such as DNA methylation, histone modification, microRNA, and so on. In summary, the findings of this review attempt to explain the role of epigenetic modification in the occurrence and development of AS. Nevertheless, there are still unknown and complicated aspects worth exploring to deepen our understanding of the pathogenesis of AS.
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  ankylosing spondylitis; epigenetic; histone; methylation; microRNA

Year:  2021        PMID: 33608999     DOI: 10.1111/1756-185X.14080

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  3 in total

1.  Risk of Ankylosing Spondylitis in Patients With Endometriosis: A Population-Based Retrospective Cohort Study.

Authors:  Zhihua Yin; Hui-Ying Low; Brian Shiian Chen; Kuo-Shu Huang; Yue Zhang; Yu-Hsun Wang; Zhizhong Ye; James Cheng-Chung Wei
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

2.  Identification of diagnostic mRNA biomarkers in whole blood for ankylosing spondylitis using WGCNA and machine learning feature selection.

Authors:  Yaguang Han; Yiqin Zhou; Haobo Li; Zhenyu Gong; Ziye Liu; Huan Wang; Bo Wang; Xiaojian Ye; Yi Liu
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

3.  PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.

Authors:  Qian Zhang; Du Jin; Xiaoyue Mou; Hengli Ye
Journal:  J Clin Lab Anal       Date:  2022-02-01       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.